FDA erteilt Micro Interventional Devices, Inc Breakthrough Device Designation für das MIA-T Percutaneous Tricuspid Annuloplasty System finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NEWTOWN, Pa., May 27, 2021 /PRNewswire/ Micro Interventional Devices (MID) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its MIA-T Percutaneous
/PRNewswire/ Micro Interventional Devices (MID) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its MIA™-T.
May 05, 2021
When surgery is needed to correct residual or recurrent mitral regurgitation (MR) after transcatheter edge-to-edge repair (TEER), chances are that the patient will need to have the valve replaced rather than repaired, shows a study using the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database.
Of patients who had mitral surgery after TEER nearly all of which would have been done with the MitraClip (Abbott) during the study period only 4.8% underwent surgical repair rather than replacement, Joanna Chikwe, MD (Cedars-Sinai Medical Center, Los Angeles, CA), reported during the virtual American Association for Thoracic Surgery 2021 meeting over the weekend.